Treatment of multiple sclerosis with hyperbaric oxygen therapy

Undersea and Hyperbaric Medicine

Volumn 28, Issue 3, 2001, Pages 117-122

  Bennett, M ^a   Heard, R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hyperbaric oxygen therapy; Multiple sclerosis

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; HYPERBARIC OXYGEN; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD;

EVIDENCE-BASED MEDICINE; HUMANS; HYPERBARIC OXYGENATION; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; SOCIETIES, MEDICAL;

EID: 0035453380     PISSN: 10662936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Compston D. The genetic epidemiology of multiple sclerosis. In: McAlpine's multiple sclerosis, Compston D, Ebers GC, Lassmann H, McDonald WI, Matthews WB, Wekerle H, eds. London: Churchill Livingstone, 1998:45-142.
2. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993;116:681-693.
3. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5:22-31.
4. Silver NC, Lai M, Symms MR, Barker GJ, McDonald WI, Miller DH. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998; 51:758-764.
5. Bar-Or A, Oliveira EM, Anderson DE, Hafler DA. Molecular pathogenesis of multiple sclerosis. J Neuroimunol 1999; 100:252-259.
6. Scheinker M. Histogenesis of the early lesions of multiple sclerosis. Arch Neurol 1943; 49:178-185.
7. Aita JF, Bennett DR, Anderson RE, Ziter F. Cranial CT appearance of acute multiple sclerosis. Neurology 1978; 28:251-255.
8. Brickner RM. The significance of localised vasoconstrictions in multiple sclerosis. Transient sudden miniature attacks of multiple sclerosis. In: Association of Respiratory, Nervous and Mental Diseases Proceedings 1950; 28:236-244.
9. James PB. Evidence for subacute fat embolism as the cause of multiple sclerosis. Lancet 1982; 1380-386.
10. Gottlieb S, Smith J, Neubauer R. The etiology of multiple sclerosis: a new and extended vascular-ischemic model. Medical Hypotheses 1990; 33:23-29.
11. rd ed. Seattle, WA: Hogrefer and Huber 1999: 373-381.
12. Waubant E, Goodkin K. Methodological problems in evaluating efficacy of a treatment for multiple sclerosis. Pathol Biol (Paris) 2000; 48:104-113.
13. Liu C, Blumhardt L. Disability outcome measures in therapeutic trials of relapsing/remitting multiple sclerosis: effects of heterogeeity of disease in placebo cohorts. J Neurol Neurosurg Psychiatry 2000; 68:450-457.
14. Weinstock-Guttman B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 2000; 59:401-410.
15. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-504.
16. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-la dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53:679-686.
17. Patti F, L'Episcopo MR, Cataldi ML, Reggio A. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand 1999; 100:283-289.
18. The European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group. Lancet 1998; 352: 1491-1497.
19. Simon Jh, Lull J, Jacobs LD, Rudick RA, et al. A longitudinal study of T1 hypointense lesions in relapsing MS. MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55:185-192.
20. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: No. 9
21. La Mantia L, Milanese C, D'Amico R. Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis. European Neurology 2000; 43:189-193.
22. Johnson KP, Brooks BR, Ford CC, Goodman A et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis 2000; 6:255-266.
23. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines, Canberra: NHMRC 1999.
24. The Federation of Hyperbaric Oxygen Centres. The experience of treating multiple sclerosis with hyperbaric oxygen http://www.miltonpark.co.uk/ms/add/preface.htm.
25. Kindwall EP, McQuillen MP, Khatri BO, Gruchow HW, Kindwall ML. Treatment of multiple sclerosis with hyperbaric oxygen. Results of a national registry. Arch Neurol 1991; 48:195-199.
26. Worthington J, DeSouza L, Forti A, Jones R, Modarres-Sadeghi H, Blaney A. A double-blind controlled cross-over trial investigating the efficacy of hyperbaric oxygen in patients with multiple sclerosis. In: Ross FC, Jones R, eds.. Multiple sclerosis. Immunological, diagnostic and therapeutic aspects. London: John Libbey, London: 1987:229-240.
27. Gottlieb SF, Neubauer RA. Multiple sclerosis: its etiology, pathogenesis and therapeutics with emphasis on the controversial use of HBO. J Hyper Med 1988; 3:143-164.
28. Fischer BH, Marks M, Reich T. Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. N Engl J Med 1983; 308:181-186.
29. Oriani G, Barbieri S, Cislaghi G, et al. Long-term hyperbaric oxygen in multiple sclerosis: a placebo-controlled double-blind trial with evoked potentials studies. J Hyper Med 1990; 5237-245.
30. Kleijnen J, Knipschild P. Hyperbaric oxygen for multiple sclerosis. Review of controlled trials. Acta Neurol Scand 1995; 91:330-334.
31. Bennett MH, Heard R. Hyperbaric oxygen for the treatment of multiple sclerosis. A critical appraisal by meta-analysis. Undersea Hyper Med 2000; 27(suppl):63-64.
32. Wiles CM, Clarke CR, Irwin HP, Edgar EF, Swan AV. Hyperbaric oxygen in multiple sclerosis: a double blind trial. Br Med J1 1986; 292:367-371.
33. Wood J, Stell R, Unsworth I, Lance J, Skuse N. A double-blind trial of hyperbaric oxygen in the treatment of multiple sclerosis. Med J Aust 1985; 143:238-241.
34. Slater GE, Anderson DA, Sherman R, Ettinger MG, Haglin J, Hitchcock C. Hyperbaric oxygen and multiple sclerosis: a double-blind, controlled study. Neurology 1985; 35(suppl 1):315.
35. Harpur GD, Suke R, Bass BH, et al. Hyperbaric oxygen therapy in chronic stable multiple sclerosis: double-blind study. Neurology 1986; 36:988-991.
36. Barnes MP, Bates D, Cartlidge N, French J, Shaw D. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry 1987; 50:1402-1406.
37. Confavreux C, Mathieu C, Chacornac R, Aimard G, Devic M. Hyperbaric oxygen in multiple sclerosis. A double-blind randomised placebo-controlled study. La Presse Med 1986; 15:1319-1322.
38. L'Hermitte F, Roullet E, Lyon-Caen O, et al. Hyperbaric oxygen treatment of chronic multiple sclerosis. Resultsof a placebo-controlled, double-blind study in 49 patients. Rev Neurol 1986; 142:201-206.
39. Erwin CW, Massey EW, Brendle AC, Shelton DL, Bennett PB. Hyperbaric oxygen influences on the visual evoked potentials in multiple sclerosis patients. Neurology 1985; 35(suppl 1):104.
40. Massey EW, Shelton DL, Pact V, et al. Hyperbaric oxygen in multiple sclerosis: a double-blind crossover study of 18 patients. Neurology 1985; 35 (suppl 1):104.
41. Murthy KN, Maurice PB, Wilmeth JB. Double-blind randomised study of hyperbaric oxygen (HBO) versus placebo in multiple sclerosis (MS). Neurology 1985; 35(suppl 1):104.
42. Nieman J, Nilsson B, Barr P, Perrins D. Hyperbaric oxygen in chronic progressive multiple sclerosis: visual evoked potentials and clinical effects. J Neurol Neurosurg Psychiatry 1985; 48:497-500.
43. Pallotta R. Hyperbaric therapy of multiple sclerosis. Min Med 1982;73:2947-2954.
44. Baixe JH. Bilan de onzo annees d'activite en medicin hyperbaric. Med Spitale, Med Subacquatique Hyperbare 1978; 17:65.
45. Boschetty V, Cemoch J. Use of HBO in various neurologic diseases (preliminary report0. Bratisi Lek Listy 1970; 53:298-301.